Zhequan Fu1, Qingyu Lin1,2, Bingxin Hu1, Yingying Zhang1, Weijia Chen1, Jing Zhu1, Yanzhao Zhao1, Hak Soo Choi3, Hongcheng Shi4,2, Dengfeng Cheng4,2. 1. Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China. 2. Shanghai Institute of Medical Imaging, Shanghai, China; and. 3. Department of Radiology, Gordon Center for Medical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 4. Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China cheng.dengfeng@zs-hospital.sh.cn shi.hongcheng@zs-hospital.sh.cn.
Abstract
Site-specific imaging agents play a key role in tumor targeting, but only a few agents are currently available for inflammation targeting. Since the P2X7 receptor (P2X7R) is a promising molecular target for inflammation, we evaluated the potential value of the 18F-labeled tracer 18F-PTTP (5-{[2-Chloro-3-(trifluoromethyl)phenyl]carbonyl}-1-pyrimidin-2-yl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridin) for targeting P2X7Rs and thus differentiating inflammation from tumors. Methods: The radioligand 18F-PTTP was achieved by a 1-step 18F-trifluoromethylation reaction. The binding affinity of the ligand for P2X7R and its stability were evaluated in vitro. Blood pharmacokinetics tests and biodistribution studies were performed in vivo. Dynamic 18F-PTTP small-animal PET/CT imaging was performed for 60 min on A549 tumor-bearing mice and inflammation-model mice for targeting differentiation. Results: 18F-PTTP was afforded with decay-corrected radiochemical yields of 2.5%-7.0%, specific activity of 296-370 MBq/μmol, and radiochemical purity over 95%. 18F-PTTP showed excellent stability in 0.9% NaCl and 0.1% bovine serum albumin, good affinity to RAW264.7 cells, and rapid blood clearance in mice. In inflammation-model mice, uptake of 18F-PTTP peaked at 5 min after injection and kept at an imageable level till 30 min, whereas no significant radioactivity uptake was found in tumor grafts till 1 h after injection. The specificity of 18F-PTTP was verified by blocking studies and histologic analysis. Conclusion: The current study provides compelling data that 18F-PTTP is a novel radioligand targeting P2X7R and has potential to screen new drugs, quantify peripheral inflammation, and distinguish inflammation from certain solid tumors.
Site-specific imaging agents play a key role in tumor targeting, but only a few agents are currently available for inflammation targeting. Since the P2X7 receptor (P2X7R) is a promising molecular target for inflammation, we evaluated the potential value of the 18F-labeled tracer 18F-PTTP (5-{[2-Chloro-3-(trifluoromethyl)phenyl]carbonyl}-1-pyrimidin-2-yl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridin) for targeting P2X7Rs and thus differentiating inflammation from tumors. Methods: The radioligand 18F-PTTP was achieved by a 1-step 18F-trifluoromethylation reaction. The binding affinity of the ligand for P2X7R and its stability were evaluated in vitro. Blood pharmacokinetics tests and biodistribution studies were performed in vivo. Dynamic 18F-PTTP small-animal PET/CT imaging was performed for 60 min on A549tumor-bearing mice and inflammation-model mice for targeting differentiation. Results:18F-PTTP was afforded with decay-corrected radiochemical yields of 2.5%-7.0%, specific activity of 296-370 MBq/μmol, and radiochemical purity over 95%. 18F-PTTP showed excellent stability in 0.9% NaCl and 0.1% bovineserum albumin, good affinity to RAW264.7 cells, and rapid blood clearance in mice. In inflammation-model mice, uptake of 18F-PTTP peaked at 5 min after injection and kept at an imageable level till 30 min, whereas no significant radioactivity uptake was found in tumor grafts till 1 h after injection. The specificity of 18F-PTTP was verified by blocking studies and histologic analysis. Conclusion: The current study provides compelling data that 18F-PTTP is a novel radioligand targeting P2X7R and has potential to screen new drugs, quantify peripheral inflammation, and distinguish inflammation from certain solid tumors.
Authors: Bieneke Janssen; Danielle J Vugts; Uta Funke; Arnold Spaans; Robert C Schuit; Esther Kooijman; Marissa Rongen; Lars R Perk; Adriaan A Lammertsma; Albert D Windhorst Journal: J Labelled Comp Radiopharm Date: 2014-07-03 Impact factor: 1.921
Authors: Leah P Dickstein; Sami S Zoghbi; Yota Fujimura; Masao Imaizumi; Yi Zhang; Victor W Pike; Robert B Innis; Masahiro Fujita Journal: Eur J Nucl Med Mol Imaging Date: 2010-11-18 Impact factor: 9.236
Authors: Elena Adinolfi; Marina Capece; Alessia Franceschini; Simonetta Falzoni; Anna L Giuliani; Alessandra Rotondo; Alba C Sarti; Massimo Bonora; Susanne Syberg; Domenica Corigliano; Paolo Pinton; Niklas R Jorgensen; Luigi Abelli; Laura Emionite; Lizzia Raffaghello; Vito Pistoia; Francesco Di Virgilio Journal: Cancer Res Date: 2014-12-26 Impact factor: 12.701
Authors: David R Owen; Astrid J Yeo; Roger N Gunn; Kijoung Song; Graham Wadsworth; Andrew Lewis; Chris Rhodes; David J Pulford; Idriss Bennacef; Christine A Parker; Pamela L StJean; Lon R Cardon; Vincent E Mooser; Paul M Matthews; Eugenii A Rabiner; Justin P Rubio Journal: J Cereb Blood Flow Metab Date: 2011-10-19 Impact factor: 6.200